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Abstract
Pregnancy was reported to be a risk factor for coronavirus disease 2019 (COVID-19), with an increased risk
for premature birth. Corticosteroids and remdesivir are used for patients with COVID-19; however, there is
no established treatment for these patients. In particular, the effective management of pregnant, critically
ill patients with COVID-19 remains unknown. We describe a 34-year-old, critically ill woman at 30 weeks of
gestation with COVID-19, who was successfully treated with remdesivir and combined high-dose
betamethasone (12 mg/day for two days) and methylprednisolone (125 mg/day for three days) followed by
steroid tapering. During treatment, fetal biophysical profile scores on obstetric ultrasound were normal; her
pregnancy course progressed well. Since high-dose corticosteroids improve fetal lung maturation and as
well as cytokine storm due to COVID-19, this case provides an insight into the management of pregnant
COVID-19 patients.
Categories: Internal Medicine, Obstetrics/Gynecology, Infectious Disease
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Introduction
Coronavirus disease 2019 (COVID-19), in which severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) induces cytokine storm and respiratory failure, has become a huge threat to human lives without the
exception of pregnant women [1-3]. COVID-19 severely affects morbidity and mortality; treatment plans
have yet to be established, including for pregnant patients [2-5]. Some drugs, such as corticosteroids and
remdesivir, are currently used as the standard treatment for COVID-19, however, their effectiveness and
safety profile for pregnant COVID-19 patients remains unclear [2-5]. Therefore, the management of
pregnant, critically ill patients is considerably challenging. Here, we present a pregnant, critically ill patient
with COVID-19, for whom a combination of high-dose corticosteroids, betamethasone and
methylprednisolone appeared to be effective.
Case Presentation
A 34-year-old Japanese woman, at 28 weeks and six days of gestation, developed fever and cough. SARS-
CoV-2 was detected by loop-mediated isothermal amplification from the saliva sample, and the lineage of
the SARS-CoV-2 variant was identified as B.1.1.7 by next-generation sequencing analysis. The patient had a
medical history of bronchial asthma without a history of smoking. Since the patient had mild symptoms,
initially she was managed symptomatically in outpatient. On the third day of COVID-19 development, she
was admitted to the former hospital. On day seven, the patient desaturated to a saturation of percutaneous
oxygen (SpO2) of 93% and ground-glass opacification in the bilateral lower lobes on chest X-ray appeared.
Oxygen supply at 2 L/min through a nasal cannula and administration of prednisolone at 40 mg per day were
initiated. However, her respiratory condition progressively deteriorated. The patient was transferred to our
tertiary hospital for higher level of care.
On admission, her body mass index was 26.7 kg/m 2. She had a body temperature of 37.0°C, a SpO2 of 94% at
4 L/min of oxygen supply through a mask, and a respiratory rate (RR) of 20 /min. Hypotension (92/58
mmHg) and sinus tachycardia (107 /min) were observed as well. No leg edema was observed. Laboratory data
showed elevated serum inflammatory markers (C-reactive protein, 6.90 mg/dL; procalcitonin, 1.120 ng/mL).
As shown in Table 1, she had slight normocytic anemia and mild liver injury, without specific antibodies for
hepatitis B and C viruses. Chest computed tomography (CT) and radiography showed bilateral multifocal
ground-glass opacities with consolidation, which were compatible with COVID-19 pneumonia (Figure 1A).
Hematological data Units (normal range)
White blood cells 11,030  /μL (3,300-8,600)
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Hemoglobin 11.1  g/dL (11.6-14.8)
MCV 93.0  fL (83.6-98.2)
Platelets 197,000  /μL (158,000-348,000)
Biochemical data Units (normal range)
Blood urea nitrogen 3.9  mg/dL (8.0-20.0)
Creatinine 0.45  mg/dL (0.46-0.79)
Sodium 136  mmoL/L (138-145)
Potassium 3.5  mmoL/L (3.6-4.8)
Chloride 106  mmoL/L (101-108)
Calcium 8.0  mg/dL (8.8-10.1)
Magnesium 1.9  mg/dL (2.0-2.5)
Inorganic phosphate 2.0  mg/dL (2.7-4.6)
AST 83  U/L (13-30)
ALT 32  U/L (7-23)
ALP (IFCC) 200  U/L (38-113)
γ-GTP 65  U/L (9-32)
Total bilirubin 0.53  mg/dL (0.40-1.50)
Creatine kinase 73  U/L (41-153)
Amylase 47  mg/dL (44-132)
Inflammatory markers Units (normal range)
LDH (IFCC) 412  U/L (124-222)
Ferritin 144.0  ng/mL (6.2-138.0)
C-reactive protein 6.90  mg/dL (<0.15)
Procalcitonin 1.120  ng/mL (<0.050)
ESR 64  mm/h (3-15)
KL-6 536  U/mL (<500)
Coagulation Units (normal range)
PT-INR 0.87  (≦2.99)
APTT 36.4  sec (26.9-38.1)
Fibrinogen 502  mg/dL (200-400)
D-dimer 1.4  μg/mL (0.0-0.9)
Metabolism and endocrine Units (normal range)
Total protein 5.7  g/dL (6.6-8.1)
Albumin 2.4  g/dL (4.1-5.1)
Uric acid 4.1  mg/dL (2.6-5.5)
Hemoglobin A1c 5.5  % (4.9-6.0)
TSH 0.11  μU/mL (0.33-4.05)
Free thyroxine 0.84  ng/dL (0.97-1.69)
BNP 30.2  pg/mL (0.0-18.4)
Infection Units (normal range)
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HBs antigen <0.005 (-)  IU/mL
HBs antibody <3.0 (-)  mIU/mL (<10.0)
HCV antibody <1.0 (-)  COI
T-spot (-)  
β-D-glucan 10 (-)  pg/mL
TABLE 1: Laboratory data on admission
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; APTT: activated partial thromboplastin time; BNP: brain
natriuretic peptide; ESR: erythrocyte sedimentation rate; γ-GTP: γ-glutamyl transpeptidase; HB: hepatitis B; HCV: hepatitis C virus; IFCC:
International Federation of Clinical Chemistry method; LDH: lactate dehydrogenase; MCV: mean corpuscular volume; PT-INR: prothorombin time-
international normalized ratio; TSH: thyroid-stimulating hormone.
FIGURE 1: Imaging findings of COVID-19 pneumonia
(A) Chest X-ray (upper) and non-contrast computed tomography (CT) (lower) showed multifocal ground-glass
opacities with consolidation in the bilateral lungs on admission. (B) Findings of chest X-ray (upper) and non-
contrast CT (lower) ameliorated after the treatment of COVID-19 (on day 19).
Her respiratory status rapidly worsened; oxygen supplementation through a high-flow nasal cannula
(HFNC), with a fraction of inspired oxygen (FiO2) of 0.7 at 40 L/min, was started on day nine in the intensive
care unit (ICU). Additionally, she had been perceiving fetal movement. Obstetric ultrasound revealed that
the fetal biophysical profile score (BPS) was 10 points; the estimated fetal weight (EFW) was normal (1,700 g
(1.2SD)).
We commenced remdesivir therapy for 10 days and as well as high-dose corticosteroid treatment with 12 mg
of betamethasone per day for two days and 125 mg of methylprednisolone per day for three days. These
high-dose corticosteroids were initiated to improve fetal lung maturation for the possibility of premature
delivery and to suppress a potential cytokine storm caused by COVID-19. Thereafter, her symptoms and
serum inflammatory markers improved with subsequent steroid tapering (Figure 2). Oxygen supply through
the HFNC was reduced gradually to 0.4 of FiO2 and decreased to 5 L/min through a mask on day 15. Findings
of COVID-19 pneumonia in chest CT and X-ray improved after treatment (Figure 1B). Corticosteroids were
administered for a total of 14 days. In the clinical course, she was administered heparin, with no findings of
thrombosis or embolism. After discharge, her EFW (1,910 g (0.7SD)) and BPS (10 points) remained normal on
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day 25. The present case was planned to be followed until her delivery date.
FIGURE 2: Clinical course
The treatment for COVID-19 was started with prednisolone at 40 mg per day, but her respiratory condition
deteriorated. Oxygen supply through a high-flow nasal cannula (HFNC) was commenced on the 9th day of
the development of COVID-19. In addition to remdesivir administration, a steroid pulse therapy of
betamethasone and methylprednisolone with subsequent steroid tapering improved her respiratory condition
and serum inflammatory markers (CRP, C-reactive protein; PCT, procalcitonin).
Discussion
A living systematic review and meta-analysis revealed that pregnant women with COVID-19 have increased
risks for being admitted to the ICU and subsequently receiving invasive respiratory support, while less
manifesting symptoms of fever, dyspnea, and myalgia [2]. Infants from mothers with COVID-19 tended to be
delivered preterm. In addition, the risks for maternal death and being admitted to the ICU could be
increased [2].
To date, several therapeutic options, such as corticosteroids and remdesivir, have been proposed for COVID-
19; however, there are no established treatments for COVID-19 [4,5]. A meta-analysis revealed that
corticosteroid, especially dexamethasone and not hydrocortisone or methylprednisolone, was associated
with an improvement of 28-day all-cause mortality in critically ill COVID-19 patients [6]. In that study,
however, doses of corticosteroid were not precisely investigated. According to the preliminary study of the
RECOVERY trial, 6 mg of dexamethasone per day for up to 10 days for COVID-19 patients receiving oxygen
is widely recommended [1]. In addition, a randomized controlled trial suggested that high-dose
methylprednisolone (250 mg per day for three days) could contribute to the clinical improvement
and decrease mortality for the early pulmonary phase of severe COVID-19 [7]. Also, an observational
comparative study suggested that methylprednisolone pulses (125-250 mg/day for three days) during the
second week of COVID-19 decreased the need for intubation or COVID-19-related mortality [8].
In accordance with the Japanese Guide to the treatment of COVID-19, Version
4.2 (https://www.mhlw.go.jp/content/000742297.pdf), our patient was started on treatment with low-dose
prednisolone (40 mg per day), not dexamethasone, because of pregnancy. However, she progressed to a
critically ill condition. Due to the concern about the possibility of cesarean section, 12 mg of betamethasone
per day for two days was administered, which was widely used in Japan to accelerate fetal lung maturation
and improve neonatal respiratory distress syndrome, necrotizing enterocolitis, and mortality [9].
Methylprednisolone pulse therapy (125 mg per day for three days) was added to suppress a COVID-19-
invoked cytokine storm in the maternal body. On the other hand, prolonged administration of
corticosteroids is not recommended because of possible adverse effects on the fetus, such as the
development of fetal adrenal insufficiency and impaired childhood neurodevelopment [10,11].
Remdesivir was reported to be associated with an improvement in the 28-day recovery and respiratory
support [12]. The antiviral agent is not recommended for routine use in pregnant women; however, since our
case was critically ill, its benefits for the reduction of the recovery time were considered [1,12,13]. Adverse
events, including liver or renal injury related to remdesivir, were not observed in the clinical course.
Conclusions
In summary, we reported a case of a critically ill pregnant woman with COVID-19, to whom remdesivir and
a combination of high-dose corticosteroids were administered. It is conceivable that short-term use of
antenatal high-dose corticosteroids, which could accelerate fetal lung maturation, improved the COVID-19
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